Long-Term Follow Up Study of Subjects Previously Administered HMI 102
NCT04348708 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 21
Last updated 2022-06-30
Summary
An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects with PAH Deficiency Previously Administered HMI 102
Conditions
- Phenylketonuria
- PAH Deficiency
Interventions
- GENETIC
-
HMI-102
HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
Sponsors & Collaborators
-
Homology Medicines, Inc
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-08-19
- Primary Completion
- 2026-01-30
- Completion
- 2026-12-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
NCT03307980 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
NCT02256917 ·Status: COMPLETED ·Phase: PHASE3
-
Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
NCT01626105 ·Status: UNKNOWN
-
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
NCT00989196 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII
NCT00543439 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Investigating Treatment Factor X in People With Factor X Deficiency
NCT00930176 ·Status: COMPLETED ·Phase: PHASE3
-
Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00243386 ·Status: COMPLETED ·Phase: PHASE4
-
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
NCT00168051 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia
NCT04878731 ·Status: COMPLETED ·Phase: PHASE1
-
Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
NCT02971969 ·Status: COMPLETED
-
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
NCT00768287 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Gene Therapy Study for Hemophilia B
NCT02484092 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
NCT02634723 ·Status: COMPLETED
-
Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
NCT02618915 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
NCT00189982 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
NCT00289536 ·Status: COMPLETED ·Phase: PHASE4
-
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
NCT04158934 ·Status: ACTIVE_NOT_RECRUITING
-
Health Related Quality of Life of Youth and Young Adults With Hemophilia A
NCT01034904 ·Status: COMPLETED
-
Natural History Study of Factor IX Treatment and Complications
NCT02502409 ·Status: UNKNOWN
-
Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A
NCT01405742 ·Status: TERMINATED ·Phase: PHASE3
-
ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
NCT02078427 ·Status: COMPLETED
-
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
NCT01712438 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
NCT00157157 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
NCT00323856 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
NCT03938792 ·Status: COMPLETED ·Phase: PHASE3